Agenus Reports Fourth Quarter and Full Year 2022 Financial Results and Outlines 2023 Objectives
14 mars 2023 07h30 HE
|
Agenus Inc.
Botensilimab plus balstilimab showed overall response rates of 23% in microsatellite stable colorectal cancer (MSS CRC), 50% in PD-(L)1 refractory non-small cell lung cancer (NSCLC) and in seven...
Agenus Cancels Conference Call to Discuss the Company’s Minority Cash Holdings at SVB in Light of Government’s SVB Deposit Access Announcement
12 mars 2023 20h29 HE
|
Agenus Inc.
LEXINGTON, Mass., March 12, 2023 (GLOBE NEWSWIRE) -- Agenus (Nasdaq: AGEN), a clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and...
Agenus Schedules Conference Call to Discuss the Company’s Minority Cash Holdings at SVB
11 mars 2023 11h24 HE
|
Agenus Inc.
LEXINGTON, Mass., March 11, 2023 (GLOBE NEWSWIRE) -- Agenus (Nasdaq: AGEN), a clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and...
Agenus to Present Botensilimab Data in Oral Plenary Session at the Society of Gynecologic Oncology 2023 Annual Meeting on Women’s Cancer
28 févr. 2023 07h30 HE
|
Agenus Inc.
LEXINGTON, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Agenus (Nasdaq: AGEN), a clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and...
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2022 Financial Report
28 févr. 2023 07h30 HE
|
Agenus Inc.
LEXINGTON, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Agenus (Nasdaq: AGEN), an immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, today announced...
Agenus to Participate in February Investor Conferences
26 janv. 2023 07h30 HE
|
Agenus Inc.
LEXINGTON, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, today announced...
Agenus Presents Clinical Data Demonstrating Durable Responses of Botensilimab/Balstilimab Combination in Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI
23 janv. 2023 07h30 HE
|
Agenus Inc.
Overall response rate (ORR) of 23% and disease control rate (DCR) of 76% in expanded cohort of 70 heavily pre-treated patients; data suggest superior benefit compared to what has been reported for...
Agenus to Participate at B Riley Securities’ 2023 Virtual Oncology Conference
10 janv. 2023 08h30 HE
|
Agenus Inc.
LEXINGTON, Mass., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline targeting cancer and infectious disease, today announced that Dr. Garo...
Agenus to Present Botensilimab Data at Late-Breaking Oral Session at ASCO-GI
21 déc. 2022 08h30 HE
|
Agenus Inc.
LEXINGTON, Mass., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to...
Agenus Data at CTOS 2022 Highlight Durable Clinical Responses of Botensilimab / Balstilimab Combination in Advanced Sarcoma
17 nov. 2022 08h30 HE
|
Agenus Inc.
Overall response rate (ORR) of 46% and disease control rate (DCR) of 69% in heavily pre-treated patients who have received a median of 3 prior lines of therapyPatient responses include sarcoma...